Prophylaxis and von Willebrand's disease (vWD)

Area of Science:

• Hematology
• Genetics
• Rheumatology

Background:

• Von Willebrand disease (vWD) is an inherited bleeding disorder affecting approximately 1% of the population.
• It stems from von Willebrand factor (vWF) deficiency or defects, impacting platelet adhesion and often lowering factor VIII (FVIII) levels.
• Joint disease is an uncommon but debilitating complication of vWD, particularly in severe forms like type 3.

Purpose of the Study:

• To review the role of prophylaxis in preventing joint disease in patients with von Willebrand disease.
• To discuss current and emerging treatment strategies for vWD, focusing on arthropathy prevention.

Main Methods:

• Literature review on vWD, its complications, and treatment options.
• Discussion of prophylactic strategies, including the role of factor concentrates.
• Highlighting an upcoming clinical trial by the Von Willebrand Disease Prophylaxis Network (vWD PN).

Main Results:

• Desmopressin is a primary treatment, while factor concentrates are alternatives when desmopressin is unsuitable.
• Recurrent joint bleeding leads to pain, degeneration, swelling, and reduced range of motion (ROM).
• Evidence suggests early prophylaxis may prevent joint bleeding and subsequent damage.

Conclusions:

• Prophylaxis is a key strategy to prevent disabling joint disease in von Willebrand disease.
• Further research, including clinical trials, is crucial to optimize prophylactic regimens for vWD patients.
• Targeting prophylaxis may significantly improve long-term joint health and quality of life for individuals with vWD.